SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

SSY Group’s Sacubitril-Valsartan Tablets Approved for Chronic Heart Failure

Valid market news retained in the public archive without immediate LiveCast distribution.

GROUP

Related stories